B3 bx725 genes soc 20181001144639
Unnamed

reVision Therapeutics

Developing treatment for Stargardt Disease which causes blindness in 32K people annually

  • Stage Product In Development
  • Industry Biotechnology
  • Location New York, NY, USA
  • Currency USD
  • Founded October 2018
  • Employees 6
  • Incorporation Type C-corp
  • Website revisiontx.com

Company Summary

reVision is developing a treatment for Stargardt disease, which causes blindness in 32K people each year and currently has no approved cure. reVision’s technology relies on an approved compound used as a non-active medium for intravenous drug delivery. Stargardt is an orphan disease and our product can qualify for accelerated approval: We anticipate to be in human clinical trials in 2020 and approved for marketing by the end of 2022.

Team

  • - As a banker led or participated in 44 financings that raised $767M for life sciences companies
    - CFO of Sellas Life Sciences (Nasdaq: SLS); took the company public through a reverse merger and raised $10.7M in funding

  • - 30 years' experience in life sciences, IP
    - Novartis, Global Head of IP
    - Baker Botts, Partner
    - Adviser to startups in all stages throughout his career

  • Default avatar
    Janine Penman
    Head of Stargardt Program

    - Clinical development subject matter expert and operations strategist with 20 years of industry-side experience supporting biopharmaceutical asset development
    - Biotherapeutics, Inc., SPR Biosciences, Parexel, Pfizer, Shire, AstraZeneca, ClinCon and Quintiles

  • 51c869a1 a44e 4b27 86e3 39cf06d16b69
    Co-founder, CSO

    - Bioengineer with expertise in retinal biomechanics and corneal physiology; research scientist in basic mechanisms that could help to alleviate Dry Eye Disease and Diabetic Retinopathy
    - Graduate of Cornell's entrepreneurship program and has held postdoctoral fellowships at Weill Cornell Medicine and the University of Leipzig, a PhD from the University of Leipzig, and Master's and Bachelor's (equivalent) from Politecnico di Milano

  • Default avatar
    Chaitanya Badwe
    Co-founder, Business Development

    - Consultant with ClearView Healthcare Partners, life sciences business development and operations
    - Chaitanya is a graduate of Cornell's entrepreneurship program and has a PhD from Weill Cornell Graduate School of Medical Sciences, a Master's degree from The Johns Hopkins University, and a Bachelor's degree from the Institute of Chemical Technology, India

Advisors